Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma

Stopped early · Phase 2

Conditions studied: Squamous Cell Carcinoma, Head and Neck Cancer, Recurrent Disease

In brief

Whether low-dose radiation in addition to Taxotere and Erbitux improves the response rate of patients with recurrent unresectable head and neck squamous cell carcinoma.

Key facts

Study ID

NCT01794845

Run by

University of Miami

People needed

5

Starts

2013-06-03

Expected to finish

2016-06-07

Last updated by the study team

2017-05-11

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have pathologically confirmed recurrence (reappearance of previously cleared) squamous cell cancer primary in the upper aerodigestive tract .Patients may have experienced more than one recurrence as long as the first recurrence occurred ≥ 6 months following the end of the prior RT.
• The recurrence must have defined bi- or uni-dimensional measurements.
• Recurrence must be confined to the head and neck above the clavicles (loco-regional recurrence).
• The patient must not be a candidate for surgical resection.
• Patients must be at least 6 months from completion of prior chemotherapy and radiation therapy.
• Patients may have received prior chemotherapy as a component of their primary treatment, but not for recurrent disease.
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
• Granulocytes ≥ 1500/mm3, platelets ≥ 100,000/mm3, serum bilirubin ≤ 1.5 mg/dl, creatinine < 1.5 mg/dl within 3 weeks prior to registration.
• Liver Function Tests (LFTs) ≤ 2 x normal (serum glutamic oxaloacetic transaminase (SGOT)/serum glutamic-pyruvic transaminase (SGPT)/Alkaline Phosphatase). If > 2 x normal, liver ultrasound or CT is required to exclude metastases. If negative for metastases, patients are eligible.
• Patients must sign a study-specific informed consent form prior to study entry.

You may not qualify if…

• Distant metastases outside of the head and neck.
• Primary disease in the nasopharynx or the salivary gland.
• Other concurrent invasive malignancies.
• Prior invasive malignancy unless disease free for at least two years (except prior in situ malignancies, e.g. cervix, breast, non-melanomatous skin cancer, etc. are permissible).
• Intercurrent medical illnesses which would impair patient tolerance to therapy or limit survival.
• Pre-existing grade ≥ 2 peripheral sensory neuropathy
• Pregnant and nursing women are excluded because of the potential teratogenic effects and potential unknown effects on nursing newborns.
• Prior history of sever hypersensitivity reaction to Docetaxol, Cetuximab or a drug with formulated with Polysorbate 80.

Where it is running

• University of Miami — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.